Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluvastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 7/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 4/20 | 1.00 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 2/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | RXRA | P19793 | 1/20 | 1.00 |
| ▸ | CCKAR | P32238 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.84 |
| ▸ | LMNA | P02545 | 1/20 | 0.84 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.84 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluvastatin SCHEMBL464787 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL2847 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL13501651 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL628757 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL6268460 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL23468028 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL2848 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL678274 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL2849 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL4295454 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111110854-A | Composition comprising a histamine release-promoting substance and an inhibitory compound | 黄泳华 | 2020-05-08 | — | — | CN | claimed |
| CN-111068064-A | Composition comprising fatty acid or derivative thereof and dihydroxyheptanoic acid derivative | 黄泳华 | 2020-04-28 | — | — | CN | claimed |
| EP-4566597-A1 | STATINS USEFUL IN THE TREATMENT OF SPLACHNIC VASCULAR DYSFUNCTIONS | Hospital Clínic de Barcelona (ES) | 2025-06-11 | — | — | EP | disclosed |
| CN-111110854-A | Composition comprising a histamine release-promoting substance and an inhibitory compound | 黄泳华 | 2020-05-08 | — | — | CN | disclosed |
| CN-111068064-A | Composition comprising fatty acid or derivative thereof and dihydroxyheptanoic acid derivative | 黄泳华 | 2020-04-28 | — | — | CN | disclosed |
| EP-3256131-A1 | ANALOGS OF 3,5-DIHYDROXYPENTANOATE FOR BONE FORMATION | Kaohsiung Medical University (TW) | 2017-12-20 | — | — | EP | disclosed |
| US-9713614-B2 | Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases | ASTRAZENECA AB (SE) | 2017-07-25 | — | — | US | disclosed |
| WO-2016130181-A1 | ANALOGS OF 3,5-DIHYDROXYPENTANOATE FOR BONE FORMATION | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2016-08-18 | — | — | WO | disclosed |
| US-9345671-B2 | Adiponectin production enhancer | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-05-24 | — | — | US | disclosed |
| US-9315447-B2 | Compositions and methods for the treatment of inflammation | A.T. Resolve Sarl (CH) | 2016-04-19 | — | — | US | disclosed |
| EP-2419399-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | C T RESOLVE SARL (CH) | 2016-03-23 | — | — | EP | disclosed |
| EP-1515717-A1 | CALCIUM SALTS OF INDOLE DERIVED STATINS | Novartis AG (CH) | 2005-03-23 | — | — | EP | disclosed |
| US-20040248813-A1 | Compounds and methods for the modulation of cd154 | CBR INSTITUTE FOR BIOMEDICAL RESEARCH, INC. | 2004-12-09 | — | — | US | disclosed |
| EP-1478640-A1 | PROCESS FOR THE MANUFACTURE OF HMG-COA REDUCTASE INHIBITORY MEVALONIC ACID DERIVATIVES | Novartis AG (CH) | 2004-11-24 | — | — | EP | disclosed |
| EP-1472228-A1 | PROCESS FOR THE MANUFACTURE OF HMG-COA REDUCTASE INHIBITORS | Novartis AG (CH) | 2004-11-03 | — | — | EP | disclosed |
| US-20040063628-A1 | Active agent delivery systems and methods for protecting and administering active agents | NEW RIVER PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2003106435-A1 | FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF | SANKYO COMPANY, LIMITED (JP) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003105837-A1 | CALCIUM SALTS OF INDOLE DERIVED STATINS | NOVARTIS AG (CH) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003070717-A1 | PROCESS FOR THE MANUFACTURE OF HMG-COA REDUCTASE INHIBITORY MEVALONIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2003-08-28 | — | — | WO | disclosed |
| WO-2003064392-A1 | PROCESS FOR THE MANUFACTURE OF HMG-COA REDUCTASE INHIBITORS | NOVARTIS AG (CH) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063628-A1 | Active agent delivery systems and methods for protecting and administering active agents | HDGF, CTSA, IAPP | HMGCR 2422/4885CYP2C9 4779/4885SIRT6 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.